Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Current Assets (2016 - 2025)

Agios Pharmaceuticals' Current Assets history spans 14 years, with the latest figure at $942.1 million for Q4 2025.

  • For Q4 2025, Current Assets fell 2.44% year-over-year to $942.1 million; the TTM value through Dec 2025 reached $942.1 million, down 2.44%, while the annual FY2025 figure was $942.1 million, 2.44% down from the prior year.
  • Current Assets reached $942.1 million in Q4 2025 per AGIO's latest filing, down from $1.0 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $2.4 billion in Q1 2021 to a low of $632.1 million in Q2 2024.
  • Average Current Assets over 5 years is $1.0 billion, with a median of $953.8 million recorded in 2024.
  • Peak YoY movement for Current Assets: skyrocketed 301.02% in 2021, then plummeted 58.59% in 2022.
  • A 5-year view of Current Assets shows it stood at $1.1 billion in 2021, then decreased by 21.75% to $832.8 million in 2022, then rose by 0.13% to $833.8 million in 2023, then increased by 15.8% to $965.6 million in 2024, then dropped by 2.44% to $942.1 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Current Assets are $942.1 million (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025).